BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 He S, Yang J, Jiang S, Li Y, Han X. Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis. Cancer Cell Int 2020;20:404. [PMID: 32863763 DOI: 10.1186/s12935-020-01496-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Zhang Y, Ni W, Qin L. RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition. Aging (Albany NY) 2021;13:21283-93. [PMID: 34510031 DOI: 10.18632/aging.203444] [Reference Citation Analysis]
3 Xue L, Liu P. Daurisoline inhibits hepatocellular carcinoma progression by restraining autophagy and promoting cispaltin-induced cell death. Biochem Biophys Res Commun 2021;534:1083-90. [PMID: 33213840 DOI: 10.1016/j.bbrc.2020.09.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Xia C, Zhang XY, Liu W, Ju M, Ju Y, Bu YZ, Wang W, Shao H. LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition. J Cell Biochem. 2018;. [PMID: 30506763 DOI: 10.1002/jcb.28074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
5 Zhang N, Zhu H, Dong YH, Wang L. Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer. Oncol Lett 2019;18:2548-53. [PMID: 31402950 DOI: 10.3892/ol.2019.10552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Xu B, Lv W, Li X, Zhang L, Lin J. Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J Cell Biochem 2019. [PMID: 30775801 DOI: 10.1002/jcb.28441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
7 Wang Y, Li M, Yu X, Chen A, Ding Y, Wang Y, Wang Y. Sinomenine hydrochloride inhibits cell survival in human hepatoma Huh7 cells. Biomed Rep 2018;8:510-6. [PMID: 29971142 DOI: 10.3892/br.2018.1084] [Reference Citation Analysis]
8 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li H, Li H, Yu W, Huang S, Liu Y, Zhang N, Yuan J, Xu X, Duan S, Hu Y. PEGylated hyaluronidase/NIR induced drug controlled release system for synergetic chemo-photothermal therapy of hepatocellular carcinoma. Eur J Pharm Sci 2019;133:127-36. [PMID: 30779981 DOI: 10.1016/j.ejps.2019.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu F, Li X, Li Y, Qi Y, Yuan H, He J, Li W, Zhou M. Designing pH-triggered drug release iron oxide nanocomposites for MRI-guided photothermal-chemoembolization therapy of liver orthotopic cancer. Biomater Sci 2019;7:1842-51. [DOI: 10.1039/c9bm00056a] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749-4763 [PMID: 31528099 DOI: 10.3748/wjg.v25.i32.4749] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
12 Lim LJ, Jin Y, Yang H, Chung AYF, Goh BKP, Chow PKH, Chan CY, Blanks WK, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients. Sci Rep 2020;10:11124. [PMID: 32636408 DOI: 10.1038/s41598-020-67742-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Li XQ, Peng WT, Shan S, Wu JJ, Li N, Du JJ, Sun JC, Chen TT, Wei W, Sun WY. β-arrestin2 regulating β2-adrenergic receptor signaling in hepatic stellate cells contributes to hepatocellular carcinoma progression. J Cancer 2021;12:7287-99. [PMID: 35003349 DOI: 10.7150/jca.59291] [Reference Citation Analysis]
14 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, Cui X, Liu X, Huang M, Cui G, Sun R. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 2021;9:687756. [PMID: 34277630 DOI: 10.3389/fcell.2021.687756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Song G, Tian L, Cheng Y, Liu J, Wang K, Li S, Li T. Antitumor activity of sevoflurane in HCC cell line is mediated by miR‐29a‐induced suppression of Dnmt3a. J Cell Biochem 2019;120:18152-61. [DOI: 10.1002/jcb.29121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 Zhang F, Liu S, Zhang N, Kuang Y, Li W, Gai S, He F, Gulzar A, Yang P. X-ray-triggered NO-released Bi-SNO nanoparticles: all-in-one nano-radiosensitizer with photothermal/gas therapy for enhanced radiotherapy. Nanoscale 2020;12:19293-307. [PMID: 32935695 DOI: 10.1039/d0nr04634e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
18 Pan XY, Huang C, Li J. The emerging roles of m6A modification in liver carcinogenesis. Int J Biol Sci 2021;17:271-84. [PMID: 33390849 DOI: 10.7150/ijbs.50003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Gao L, Wang K, Zhang N, Li J, Qin X, Wang X. 1 H Nuclear Magnetic Resonance Based Metabolomics Approach Reveals the Metabolic Mechanism of (−)-5-Hydroxy-equol against Hepatocellular Carcinoma Cells in Vitro. J Proteome Res 2018;17:1833-43. [DOI: 10.1021/acs.jproteome.7b00853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
20 Gan W, Yi Y, Fu Y, Huang J, Lu Z, Jing C, Fan J, Zhou J, Qiu S. Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. J Cancer 2018;9:148-56. [PMID: 29290780 DOI: 10.7150/jca.22246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
21 Peng S, Chen Y, Gong Y, Li Z, Xie R, Lin Y, Zou B, Li J, Zeng L. Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines. Cytokine 2019;119:81-9. [PMID: 30903867 DOI: 10.1016/j.cyto.2019.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Wu J, Yuan J, Ye B, Wu Y, Xu Z, Chen J, Chen J. Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy. Front Pharmacol 2018;9:663. [PMID: 30065648 DOI: 10.3389/fphar.2018.00663] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Zhang R, Mo WJ, Huang LS, Chen JT, Wu WZ, He WY, Feng ZB. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma. Bioengineered 2021;12:855-74. [PMID: 33641617 DOI: 10.1080/21655979.2021.1890399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jie M, Hai-xia L, Fei-fei T, Shu-ling L, Tian-yi F, Xue-qian W, Qing-guo W, Fa-feng C. Systematic Investigation of Berberine for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Digital Chinese Medicine 2019;2:127-35. [DOI: 10.1016/j.dcmed.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Sharifian M, Baharvand P, Moayyedkazemi A. Liver Cancer: New Insights into Surgical and Nonsurgical Treatments. CCTR 2021;17:197-206. [DOI: 10.2174/1573394717666210219104201] [Reference Citation Analysis]
26 Sun Y, Zhao H, Wu M, Xu J, Zhu S, Gao J. Identifying critical states of hepatocellular carcinoma based on landscape dynamic network biomarkers. Comput Biol Chem 2020;85:107202. [PMID: 31951859 DOI: 10.1016/j.compbiolchem.2020.107202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Bozdag M, Ferraroni M, Ward C, Carta F, Bua S, Angeli A, Langdon SP, Kunkler IH, Al-Tamimi AS, Supuran CT. Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells. Eur J Med Chem 2019;182:111600. [PMID: 31419777 DOI: 10.1016/j.ejmech.2019.111600] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
28 Li GX, Ding ZY, Wang YW, Liu TT, Chen WX, Wu JJ, Xu WQ, Zhu P, Zhang BX. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. J Cell Physiol. 2019;234:11942-11950. [PMID: 30536816 DOI: 10.1002/jcp.27882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lian B, Wei H, Pan R, Sun J, Zhang B, Wu J, Li X, Tian G. Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4. Int J Nanomedicine 2021;16:457-67. [PMID: 33488080 DOI: 10.2147/IJN.S283793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yamashita H, Surapureddi S, Kovi RC, Bhusari S, Ton TV, Li JL, Shockley KR, Peddada SD, Gerrish KE, Rider CV, Hoenerhoff MJ, Sills RC, Pandiri AR. Unique microRNA alterations in hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. Arch Toxicol 2020;94:2523-41. [PMID: 32306082 DOI: 10.1007/s00204-020-02749-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Huang Y, Hu L, Huang S, Xu W, Wan J, Wang D, Zheng G, Xia Z. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Int J Nanomedicine 2018;13:8309-23. [PMID: 30584302 DOI: 10.2147/IJN.S184379] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
32 Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, Chen J, Hu YW, Zheng L, Wang Q. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer 2018;17:93. [PMID: 29803224 DOI: 10.1186/s12943-018-0841-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 19.8] [Reference Citation Analysis]
33 Lu Z, Chang L, Zhou H, Liu X, Li Y, Mi T, Tong D. Arctigenin Attenuates Tumor Metastasis Through Inhibiting Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma via Suppressing GSK3β-Dependent Wnt/β-Catenin Signaling Pathway In Vivo and In Vitro. Front Pharmacol 2019;10:937. [PMID: 31555129 DOI: 10.3389/fphar.2019.00937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
34 Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev 2020;154-155:102-22. [PMID: 32650041 DOI: 10.1016/j.addr.2020.07.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 32.5] [Reference Citation Analysis]
35 Shen S, Wang Y. Expression and Prognostic Role of E2F2 in Hepatocellular Carcinoma. Int J Gen Med 2021;14:8463-72. [PMID: 34824545 DOI: 10.2147/IJGM.S334033] [Reference Citation Analysis]
36 Cao J, Huang J, Gui S, Chu X. Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer. Int J Nanomedicine 2021;16:3725-39. [PMID: 34103913 DOI: 10.2147/IJN.S207607] [Reference Citation Analysis]
37 Liang C, Niu J, Wang X, Zhang ZS, Yang RH, Yao X, Liu FY, Li WQ, Pei SH, Sun H, Wang CJ, Fang D, Xie SQ. P300-dependent acetylation of histone H3 is required for epidermal growth factor receptor-mediated high-mobility group protein A2 transcription in hepatocellular carcinoma. Cancer Sci 2021;112:679-90. [PMID: 33164305 DOI: 10.1111/cas.14729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang G, Zhao W, Wang H, Qiu G, Jiang Z, Wei G, Li X. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2. Med Sci Monit 2019;25:7209-17. [PMID: 31553714 DOI: 10.12659/MSM.919219] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
39 Li M, Chen J, Yu X, Xu S, Li D, Zheng Q, Yin Y. Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP. Cells 2019;8:E358. [PMID: 30999669 DOI: 10.3390/cells8040358] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
40 Deng Y, Wei Z, Huang M, Xu G, Wei W, Peng B, Nong S, Qin H. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p. J Cell Mol Med 2020;24:1848-65. [PMID: 31880390 DOI: 10.1111/jcmm.14881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Yang L, Jiang J. GAS5 Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b. Biomed Res Int. 2019;2019:2973289. [PMID: 30733959 DOI: 10.1155/2019/2973289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
42 Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W, Shen J, Lu M, Tang Z, Ju L, Wang Y, Jiao R, Xia Y, Huang G, Yang L, Li Y, Zhang J, Wong VKW, Jiang Z. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. J Exp Clin Cancer Res 2018;37:321. [PMID: 30572915 DOI: 10.1186/s13046-018-1005-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
43 Teran-Saavedra NG, Sarabia-Sainz JA, Silva-Campa E, Burgara-Estrella AJ, Guzmán-Partida AM, Ramos-Clamont Montfort G, Pedroza-Montero M, Vazquez-Moreno L. Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma. Molecules 2019;24:E1382. [PMID: 30970533 DOI: 10.3390/molecules24071382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
44 Ouyang P, Qing Y, Zou S, Fang C, Han J, Yang Y, Li H, Wang Z, Du J. Sensitive detection of miR-122 via toehold-promoted strand displacement reaction and enzyme-assisted cycle amplification. Biochemical Engineering Journal 2022. [DOI: 10.1016/j.bej.2022.108576] [Reference Citation Analysis]
45 Wang K, Fang J, Qin X, Du G, Gao L. Uncovering the anti-metastasis effects and mechanisms of capsaicin against hepatocellular carcinoma cells by metabolomics. Journal of Functional Foods 2019;60:103431. [DOI: 10.1016/j.jff.2019.103431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Ding J, Tang B, Liu X, Bai X, Wang Y, Li S, Li J, Liu M, Wang X. Excretory-secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis. Acta Trop 2022;225:106172. [PMID: 34627760 DOI: 10.1016/j.actatropica.2021.106172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zhu K, Zhou L, Zou M, Ning S, Liu S, Zhou Y, Du K, Zhang X, Xia X. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency. J Pharm Sci 2020;109:2038-47. [PMID: 32173319 DOI: 10.1016/j.xphs.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma.Biomed Pharmacother. 2019;119:109402. [PMID: 31514072 DOI: 10.1016/j.biopha.2019.109402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
49 Sun DE, Ye SY. Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment. Cancer Manag Res 2020;12:6103-12. [PMID: 32765105 DOI: 10.2147/CMAR.S253042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
50 Kim SH, Wang WH, Wang JP, Hsieh CH, Fang K. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. Biomed Pharmacother 2018;99:997-1008. [PMID: 29653488 DOI: 10.1016/j.biopha.2018.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Yang C, Mai Z, Liu C, Yin S, Cai Y, Xia C. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. Molecules 2022;27:3513. [PMID: 35684449 DOI: 10.3390/molecules27113513] [Reference Citation Analysis]
52 Wang M, Hu Y, Zi Y, Huang W. Functionalized hybridization of bismuth nanostructures for highly improved nanophotonics. APL Materials 2022;10:050901. [DOI: 10.1063/5.0091341] [Reference Citation Analysis]
53 Lin B, Wang Y, Zhao K, Lü WD, Hui X, Ma Y, Lv R. Exosome-based rare earth nanoparticles for targeted in situ and metastatic tumor imaging with chemo-assisted immunotherapy. Biomater Sci 2021. [PMID: 34940770 DOI: 10.1039/d1bm01809d] [Reference Citation Analysis]
54 Wu P, Xiao Y, Guo T, Wang Y, Liao S, Chen L, Liu Z. Identifying miRNA-mRNA Pairs and Novel miRNAs from Hepatocelluar Carcinoma miRNomes and TCGA Database. J Cancer. 2019;10:2552-2559. [PMID: 31258761 DOI: 10.7150/jca.28167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
55 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
56 He L, Fan X, Li Y, Cui B, Shi Z, Zhou D, Lin H. Aberrant methylation status of SPG20 promoter in hepatocellular carcinoma: A potential tumor metastasis biomarker. Cancer Genet 2019;233-234:48-55. [PMID: 31109594 DOI: 10.1016/j.cancergen.2019.04.003] [Reference Citation Analysis]
57 Kong R, Liu H, Shi Y, Man Q, Liu S. COL14A1 promotes self-renewal of human liver cancer stem cells through activation of ERK signaling. Journal of Bio-X Research 2021;4:10-7. [DOI: 10.1097/jbr.0000000000000087] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yang X, Liu J, Liang Q, Sun G. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. Fundam Clin Pharmacol 2021;35:690-9. [PMID: 33015852 DOI: 10.1111/fcp.12608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Qiu Y, Shan W, Yang Y, Jin M, Dai Y, Yang H, Jiao R, Xia Y, Liu Q, Ju L, Huang G, Zhang J, Yang L, Li L, Li Y. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α. Cell Death Discov 2019;5:120. [PMID: 31341646 DOI: 10.1038/s41420-019-0200-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
60 Li Y, Wu B, Sun R, Zhao M, Li N. miR-93-5p knockdown repressed hepatocellular carcinoma progression via increasing ERBB4 and TETs-dependent DNA demethylation. Autoimmunity 2021;:1-14. [PMID: 34435526 DOI: 10.1080/08916934.2021.1969552] [Reference Citation Analysis]
61 Zhao F, Liu A, Gong X, Chen H, Wei J, Chen B, Chen S, Yang R, Fan Y, Mao R. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis. Tumori 2021;:3008916211026019. [PMID: 34165025 DOI: 10.1177/03008916211026019] [Reference Citation Analysis]
62 Qiao Y, Wang J, Karagoz E, Liang B, Song X, Shang R, Evert K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP, Chen X. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. Hepatology 2019;70:2003-17. [PMID: 30737831 DOI: 10.1002/hep.30556] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
63 Xu J, Xiao X, Yan B, Yuan Q, Dong X, Du Q, Zhang J, Shan L, Ding Z, Zhou L, Efferth T. Green tea-derived theabrownin induces cellular senescence and apoptosis of hepatocellular carcinoma through p53 signaling activation and bypassed JNK signaling suppression. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02468-3] [Reference Citation Analysis]
64 Li M, Gao J, Li D, Yin Y. CEP55 Promotes Cell Motility via JAK2⁻STAT3⁻MMPs Cascade in Hepatocellular Carcinoma. Cells 2018;7:E99. [PMID: 30096813 DOI: 10.3390/cells7080099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
65 Huang S, Ren D, Wu X, Li M, Yu X, Nie X, Wang Y, Wang Y. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer. Curr Top Med Chem 2020;20:2493-505. [PMID: 32703132 DOI: 10.2174/1568026620666200722110244] [Reference Citation Analysis]
66 Gong B, Kao Y, Zhang C, Sun F, Zhao H. Systematic Investigation of Scutellariae Barbatae Herba for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Evid Based Complement Alternat Med 2018;2018:4365739. [PMID: 30584453 DOI: 10.1155/2018/4365739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
67 Lin CS, Liang Y, Su SG, Zheng YL, Yang X, Jiang N, Fu L, Zhou J, Zhang Y, Deng R, Wang CH, Lu SX, Huang YH, Liu LL, Zhang C, Yun JP. Nucleoporin 93 mediates β-catenin nuclear import to promote hepatocellular carcinoma progression and metastasis. Cancer Lett 2021;526:236-47. [PMID: 34767927 DOI: 10.1016/j.canlet.2021.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Li W, Hao J, Zhang L, Cheng Z, Deng X, Shu G. Astragalin Reduces Hexokinase 2 through Increasing miR-125b to Inhibit the Proliferation of Hepatocellular Carcinoma Cells in Vitro and in Vivo. J Agric Food Chem 2017;65:5961-72. [PMID: 28654261 DOI: 10.1021/acs.jafc.7b02120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
69 Xu B, Lv W, Li X, Zhang L, Lin J. Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues. Oncol Lett 2019;17:5187-92. [PMID: 31186734 DOI: 10.3892/ol.2019.10210] [Reference Citation Analysis]
70 Hou JY, Wu HY, He RQ, Lin P, Dang YW, Chen G. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases. Pathol Res Pract 2019;215:177-94. [PMID: 30473171 DOI: 10.1016/j.prp.2018.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lin X, Xiang X, Feng B, Zhou H, Wang T, Chu X, Wang R. Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. Front Oncol 2021;11:670838. [PMID: 34249710 DOI: 10.3389/fonc.2021.670838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Yang WJ, Sun YF, Jin AL, Lv LH, Zhu J, Wang BL, Zhou Y, Zhang CY, Wang H, Hu B, Wang PX, Te L, Pan BS, Zhou J, Fan J, Yang XR, Guo W. BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death Dis 2020;11:895. [PMID: 33093445 DOI: 10.1038/s41419-020-03115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Ye Z, Wu W, Qin Y, Hu J, Liu C, Seeberger PH, Yin J. An Integrated Therapeutic Delivery System for Enhanced Treatment of Hepatocellular Carcinoma. Adv Funct Mater 2018;28:1706600. [DOI: 10.1002/adfm.201706600] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
74 Ding L, Yu Q, Yang S, Yang WJ, Liu T, Xian JR, Tian TT, Li T, Chen W, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. Front Immunol 2022;13:831101. [PMID: 35371079 DOI: 10.3389/fimmu.2022.831101] [Reference Citation Analysis]
75 Cui H, Zhang Y, Zhang Q, Chen W, Zhao H, Liang J. A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. Cancer Med 2017;6:2932-41. [PMID: 29047230 DOI: 10.1002/cam4.1180] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
76 Niu J, Li W, Liang C, Wang X, Yao X, Yang R, Zhang Z, Liu H, Liu F, Pei S, Li W, Sun H, Fang D, Xie S. EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3. Sci Signal 2020;13. [DOI: 10.1126/scisignal.abb5727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
77 Rajput A, Pingale P, Telange D, Chalikwar S, Borse V. Lymphatic transport system to circumvent hepatic metabolism for oral delivery of lipid-based nanocarriers. Journal of Drug Delivery Science and Technology 2021;66:102934. [DOI: 10.1016/j.jddst.2021.102934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Reshitko GS, Yamansarov EY, Evteev SA, Lopatukhina EV, Shkil' DO, Saltykova IV, Lopukhov AV, Kovalev SV, Lobov AN, Kislyakov IV, Burenina OY, Klyachko NL, Garanina AS, Dontsova OA, Ivanenkov YA, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor. Bioconjug Chem 2020;31:1313-9. [PMID: 32379426 DOI: 10.1021/acs.bioconjchem.0c00202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Wang G, Ding B, Sun L, Guo J, Wang S, Li W, Zhang Y, Lv J, Qiu W. Construction and Validation of a Necroptosis-Related Signature Associated With the Immune Microenvironment in Liver Hepatocellular Carcinoma. Front Genet 2022;13:859544. [DOI: 10.3389/fgene.2022.859544] [Reference Citation Analysis]
80 Liu S, Qiu J, He W, Geng C, He G, Liu C, Cai D, Liu X, Tian B, Pan H. TUG1 long non-coding RNA enlists the USF1 transcription factor to overexpress ROMO1 leading to hepatocellular carcinoma growth and metastasis. MedComm (2020) 2020;1:386-99. [PMID: 34766130 DOI: 10.1002/mco2.38] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
82 Chen H, Wang H, Yu X, Zhou S, Zhang Y, Wang Z, Huang S, Wang Z. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway. BMC Cancer 2020;20:853. [PMID: 32891122 DOI: 10.1186/s12885-020-07367-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
83 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 21.7] [Reference Citation Analysis]
84 Singh A, Shafi S, Upadhyay T, Najmi AK, Kohli K, Pottoo FH. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Curr Top Med Chem 2020;20:1839-54. [PMID: 32579503 DOI: 10.2174/1568026620666200624161801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Nair AB, Shah J, Al-Dhubiab BE, Patel SS, Morsy MA, Patel V, Chavda V, Jacob S, Sreeharsha N, Shinu P, Attimarad M, Venugopala KN. Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules 2019;24:E4566. [PMID: 31847085 DOI: 10.3390/molecules24244566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
86 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Zeng T, Tang Z, Liang L, Suo D, Li L, Li J, Yuan Y, Guan XY, Li Y. PDSS2-Del2, a new variant of PDSS2, promotes tumor cell metastasis and angiogenesis in hepatocellular carcinoma via activating NF-κB. Mol Oncol 2020;14:3184-97. [PMID: 33064899 DOI: 10.1002/1878-0261.12826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Elbadry MM, Tharwat M, Mohammad EF, Abdo EF. Diagnostic accuracy of serum endothelin-1 in patients with HCC on top of liver cirrhosis. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00030-2] [Reference Citation Analysis]
89 Hong F, Gao Y, Li Y, Zheng L, Xu F, Li X. Inhibition of HIF1A-AS1 promoted starvation-induced hepatocellular carcinoma cell apoptosis by reducing HIF-1α/mTOR-mediated autophagy. World J Surg Oncol 2020;18:113. [PMID: 32473641 DOI: 10.1186/s12957-020-01884-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Deng L, Wang C, He C, Chen L. Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p. Cancer Biomark 2021;30:223-35. [PMID: 33136092 DOI: 10.3233/CBM-201633] [Reference Citation Analysis]
91 Wu W, Zhou Z, Chen C, Chen M. Circ_0061395 functions as an oncogenic gene in hepatocellular carcinoma by acting as a miR-1182 sponge. Cell Cycle 2022;:1-14. [PMID: 35775884 DOI: 10.1080/15384101.2022.2092177] [Reference Citation Analysis]
92 Jiang P, Han W, Fu Y, Chen Q. The Hsa_circ_0091579/miR-940/TACR1 Axis Regulates the Development of Hepatocellular Carcinoma. Cancer Manag Res 2020;12:9087-96. [PMID: 33061603 DOI: 10.2147/CMAR.S259243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 2019;23:341-50. [DOI: 10.1007/s11030-018-9875-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Kong W, Zheng J, Chen L, Zuo X, Wang H, Wang X, Yao J, Chen W. Mean corpuscular hemoglobin concentration correlates with prognosis of resected hepatocellular carcinoma. Biomark Med 2020;14:259-70. [PMID: 32134324 DOI: 10.2217/bmm-2019-0224] [Reference Citation Analysis]
95 Yin Y, Zhou L, Zhan R, Zhang Q, Li M. Identification of WDR12 as a novel oncogene involved in hepatocellular carcinoma propagation. Cancer Manag Res 2018;10:3985-93. [PMID: 30310320 DOI: 10.2147/CMAR.S176268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022;13:146. [PMID: 35165269 DOI: 10.1038/s41419-022-04583-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Ji Y, Chen H, Gow W, Ma L, Jin Y, Hui B, Yang Z, Wang Z. Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma. Oncol Lett 2020;20:208. [PMID: 32963614 DOI: 10.3892/ol.2020.12071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Han Y, Li Z, Wu Q, Liu H, Sun Z, Wu Y, Luo J. B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma. BMC Cancer 2022;22:392. [PMID: 35410157 DOI: 10.1186/s12885-022-09442-2] [Reference Citation Analysis]
100 Lv J, Liu J, Xiao M, Xu H, Xu C, Zhang X, Tang L, Jiang F, Zhou Y, Zhang Z, Qu L, Lu C. ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma. Pathol Res Pract 2018;214:1356-61. [PMID: 30049513 DOI: 10.1016/j.prp.2018.05.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
101 Hu B, An HM, Yan X, Zheng JL, Huang XW, Li M. Traditional Chinese medicine formulation Yanggan Jiedu Sanjie inhibits TGF-β1-induced epithelial-mesenchymal transition and metastatic potential in human hepatocarcinoma Bel-7402 cells. BMC Complement Altern Med 2019;19:67. [PMID: 30876428 DOI: 10.1186/s12906-019-2477-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
102 Mansouri V, Beheshtizadeh N, Gharibshahian M, Sabouri L, Varzandeh M, Rezaei N. Recent advances in regenerative medicine strategies for cancer treatment. Biomed Pharmacother 2021;141:111875. [PMID: 34229250 DOI: 10.1016/j.biopha.2021.111875] [Reference Citation Analysis]
103 Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, Zhang S. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int 2021;21:586. [PMID: 34717619 DOI: 10.1186/s12935-021-02298-9] [Reference Citation Analysis]
104 Wu S, Zhang Z, Cheng N, Xiong X, Yang L. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. Surgical Oncology 2019;29:159-67. [DOI: 10.1016/j.suronc.2019.05.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer 2020;8:e000317. [PMID: 32179631 DOI: 10.1136/jitc-2019-000317] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
106 Jiang W, Zhao T, Zhen X, Jin C, Li H, Ha J. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. Front Pharmacol 2022;13:920436. [DOI: 10.3389/fphar.2022.920436] [Reference Citation Analysis]
107 Zhu J, Zhang W, Wang D, Li S, Wu W. Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate. Exp Ther Med. 2018;16:1639-1646. [PMID: 30186382 DOI: 10.3892/etm.2018.6416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
108 Hu Q, Ma X, Li C, Zhou C, Chen J, Gu X. Downregulation of THRSP Promotes Hepatocellular Carcinoma Progression by Triggering ZEB1 Transcription in an ERK-dependent Manner. J Cancer 2021;12:4247-56. [PMID: 34093825 DOI: 10.7150/jca.51657] [Reference Citation Analysis]
109 Zhang X, Lv J, Luo H, Liu Z, Xu C, Zhou D, Tang L, Zhang Z, Liu J, Xiao M, Yao Y, Qu L, Lu C. Nucleostemin promotes hepatocellular carcinoma by regulating the function of STAT3. Exp Cell Res 2020;387:111748. [PMID: 31785228 DOI: 10.1016/j.yexcr.2019.111748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
110 Jiang J, Zhang Y, Xu R, Ren L, Chen J, Lu H. PRIM1 promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo. J Cancer 2020;11:6601-11. [PMID: 33046981 DOI: 10.7150/jca.47870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Ji Y, Shen J, Li M, Zhu X, Wang Y, Ding J, Jiang S, Chen L, Wei W. RMP/URI inhibits both intrinsic and extrinsic apoptosis through different signaling pathways. Int J Biol Sci 2019;15:2692-706. [PMID: 31754340 DOI: 10.7150/ijbs.36829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
112 Zhong X, Kan A, Zhang W, Zhou J, Zhang H, Chen J, Tang S. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma. Aging (Albany NY) 2019;11:5483-97. [PMID: 31375643 DOI: 10.18632/aging.102132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
113 Guo Y, Cai X, Lu H, Li Q, Zheng Y, Lin Z, Cheng Z, Yang M, Zhang L, Xiang L, Yang X. 17β-Estradiol Promotes Apoptosis of HepG2 Cells Caused by Oxidative Stress by Increasing Foxo3a Phosphorylation. Front Pharmacol 2021;12:607379. [PMID: 33790784 DOI: 10.3389/fphar.2021.607379] [Reference Citation Analysis]
114 Rong X, Sun-waterhouse D, Wang D, Jiang Y, Li F, Chen Y, Zhao S, Li D. The Significance of Regulatory MicroRNAs: Their Roles in Toxicodynamics of Mycotoxins and in the Protection Offered by Dietary Therapeutics Against Mycotoxin-Induced Toxicity: MiRNAs and toxicity of mycotoxins…. Comprehensive Reviews in Food Science and Food Safety 2019;18:48-66. [DOI: 10.1111/1541-4337.12412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY, Qiu SJ, Pan BS, Zhou J, Fan J, Yang XR, Guo W. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol 2019;12:37. [PMID: 30971294 DOI: 10.1186/s13045-019-0724-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
116 Wang H, Liao P, Zeng SX, Lu H. Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells. Cancer Biol Ther 2020;21:269-77. [PMID: 31747859 DOI: 10.1080/15384047.2019.1685289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Wang J, Peng R, Zhang Z, Zhang Y, Dai Y, Sun Y. Identification and Validation of Key Genes in Hepatocellular Carcinoma by Bioinformatics Analysis. Biomed Res Int 2021;2021:6662114. [PMID: 33688500 DOI: 10.1155/2021/6662114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Zhou B, Lu Q, Liu J, Fan L, Wang Y, Wei W, Wang H, Sun G. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. Int J Biol Sci 2019;15:1905-20. [PMID: 31523192 DOI: 10.7150/ijbs.32550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
119 Qiu C, Liu K, Zhang S, Gao S, Chen W, Li D, Huang Y. Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination. Drug Des Devel Ther 2020;14:993-1001. [PMID: 32184568 DOI: 10.2147/DDDT.S231814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
120 Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, Argenziano M, Cavalli R, Toffoli G, Macor P. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. J Oncol 2020;2020:4638192. [PMID: 32184825 DOI: 10.1155/2020/4638192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
121 Wang Y, Zhang P, Yuan M, Li X. Overexpression of miRNA-21 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma Cells via Suppressing SMAD7. Technol Cancer Res Treat 2019;18:1533033819878686. [PMID: 31554487 DOI: 10.1177/1533033819878686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
122 Wang K, Ye X, Yin C, Ren Q, Chen Y, Qin X, Duan C, Lu A, Gao L, Guan D. Computational Metabolomics Reveals the Potential Mechanism of Matrine Mediated Metabolic Network Against Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:859236. [DOI: 10.3389/fcell.2022.859236] [Reference Citation Analysis]
123 Gao L, Wang KX, Zhou YZ, Fang JS, Qin XM, Du GH. Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci Rep 2018;8:624. [PMID: 29330507 DOI: 10.1038/s41598-017-18325-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
124 Nabi AA, Atta SA, El-Ahwany E, Elzayat E, Saleh H. Taurine Upregulates miRNA-122-5p Expression and Suppresses the Metabolizing Enzymes of Glycolytic Pathway in Hepatocellular Carcinoma. Mol Biol Rep 2021;48:5549-59. [PMID: 34313924 DOI: 10.1007/s11033-021-06571-y] [Reference Citation Analysis]
125 Zhang S, Jing J, Meng L, Xu B, Ma X, Tian W. Peptide-Conjugated Aggregation-Induced Emission Fluorogenic Probe for Glypican-3 Protein Detection and Hepatocellular Carcinoma Cells Imaging. Chemosensors 2022;10:195. [DOI: 10.3390/chemosensors10050195] [Reference Citation Analysis]
126 Li M, Jin C, Xu M, Zhou L, Li D, Yin Y. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling. Cell Commun Signal 2017;15:52. [PMID: 29246230 DOI: 10.1186/s12964-017-0208-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
127 Zhao X, Song Q, Miao G, Zhu X. MicroRNA-3651 promotes the growth and invasion of hepatocellular carcinoma cells by targeting PTEN. Onco Targets Ther 2019;12:7045-54. [PMID: 31695418 DOI: 10.2147/OTT.S213705] [Reference Citation Analysis]
128 Du Z, Mao Y, Zhang P, Hu J, Fu J, You Q, Yin J. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2021;13:35518-32. [PMID: 34286569 DOI: 10.1021/acsami.1c09610] [Reference Citation Analysis]
129 Wang KX, Chen YP, Lu AP, Du GH, Qin XM, Guan DG, Gao L. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC. J Ethnopharmacol 2021;274:114043. [PMID: 33753143 DOI: 10.1016/j.jep.2021.114043] [Reference Citation Analysis]
130 He B, Lu P, Guan L, Li T, Zhang L, Zhu QG, Ding XX, Zhang SM, Chen XM, Zhao J, Lin S, Liu ZZ, Liu FE, Ma W, Zhang HQ. Identifying key regulating miRNAs in hepatocellular carcinomas by an omics' method. Oncotarget 2017;8:103919-30. [PMID: 29262610 DOI: 10.18632/oncotarget.21865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Chen Z, Ma Y, Pan Y, Zuo S, Zhu H, Yu C, Zhu C, Sun C. Long Noncoding RNA RP5-833A20.1 Suppresses Tumorigenesis In Hepatocellular Carcinoma Through Akt/ERK Pathway By Targeting miR-18a-5p. Onco Targets Ther 2019;12:10717-26. [PMID: 31827329 DOI: 10.2147/OTT.S219797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
132 Guo M, Li Y, Lin Z, Zhao M, Xiao M, Wang C, Xu T, Xia Y, Zhu B. Surface decoration of selenium nanoparticles with curcumin induced HepG2 cell apoptosis through ROS mediated p53 and AKT signaling pathways. RSC Adv 2017;7:52456-64. [DOI: 10.1039/c7ra08796a] [Cited by in Crossref: 27] [Article Influence: 5.4] [Reference Citation Analysis]
133 Khan SA, Lee TKW. Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. Front Pharmacol 2022;13:968148. [DOI: 10.3389/fphar.2022.968148] [Reference Citation Analysis]
134 Wu Y, Min J, Ge C, Shu J, Tian D, Yuan Y, Zhou D. Interleukin 22 in Liver Injury, Inflammation and Cancer. Int J Biol Sci 2020;16:2405-13. [PMID: 32760208 DOI: 10.7150/ijbs.38925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
135 Dai H, Li M, Yang W, Sun X, Wang P, Wang X, Su J, Wang X, Hu X, Zhao M. Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling. Aging (Albany NY) 2020;12:11717-31. [PMID: 32530437 DOI: 10.18632/aging.103338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
136 Zhao L, Zheng R, Liu L, Chen X, Guan R, Yang N, Chen A, Yu X, Cheng H, Li S. Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. Biomaterials 2021;275:120970. [PMID: 34146889 DOI: 10.1016/j.biomaterials.2021.120970] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
137 Nakajima T, Ninomiya Y, Nenoi M. Radiation-Induced Reactions in The Liver - Modulation of Radiation Effects by Lifestyle-Related Factors. Int J Mol Sci 2018;19:E3855. [PMID: 30513990 DOI: 10.3390/ijms19123855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
138 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
139 Zhang S, Zhang F, Chen Q, Wan C, Xiong J, Xu J. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. J Exp Clin Cancer Res 2019;38:467. [PMID: 31727171 DOI: 10.1186/s13046-019-1462-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
140 Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, Otake K, Kawamata Y. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochem Biophys Res Commun 2017;493:800-6. [PMID: 28843857 DOI: 10.1016/j.bbrc.2017.08.088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
141 Liang L, Zhao L, Wang Y, Wang Y. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells. Mol Pharm 2021;18:1003-13. [PMID: 33527831 DOI: 10.1021/acs.molpharmaceut.0c00976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Song L, Wang Z, Wang Y, Guo D, Yang J, Chen L, Tan N. Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells. Molecules 2017;22:E1934. [PMID: 29137114 DOI: 10.3390/molecules22111934] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
143 Mokhtari S, Solati-hashjin M, Khosrowpour Z, Gholipourmalekabadi M. Layered double hydroxide-galactose as an excellent nanocarrier for targeted delivery of curcumin to hepatocellular carcinoma cells. Applied Clay Science 2021;200:105891. [DOI: 10.1016/j.clay.2020.105891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
144 Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF, Chen X. Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death Dis 2020;11:91. [PMID: 32019910 DOI: 10.1038/s41419-020-2289-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
145 Guo J, Zeng H, Liu Y, Shi X, Liu Y, Liu C, Chen Y. Multicomponent thermosensitive lipid complexes enhance desmoplastic tumor therapy through boosting anti-angiogenesis and synergistic strategy. Int J Pharm 2021;601:120533. [PMID: 33781886 DOI: 10.1016/j.ijpharm.2021.120533] [Reference Citation Analysis]
146 Lee SY, Choi JW, Lee JY, Kim DD, Kim HC, Cho HJ. Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor. Drug Deliv 2018;25:1472-83. [PMID: 29909706 DOI: 10.1080/10717544.2018.1480673] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
147 Liu TS, Shen QH, Zhou XY, Shen X, Lai L, Hou XM, Liu K. Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis. J Clin Anesth 2021;75:110467. [PMID: 34343737 DOI: 10.1016/j.jclinane.2021.110467] [Reference Citation Analysis]
148 Chen H, Jiang S, Zhang P, Ren Z, Wen J. Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization. Int Immunopharmacol 2021;99:107960. [PMID: 34284286 DOI: 10.1016/j.intimp.2021.107960] [Reference Citation Analysis]
149 Wang F, Sun D, Zhang N, Chen Z. The efficacy and safety of controlled low central venous pressure for liver resection: a systematic review and meta-analysis. Gland Surg 2020;9:311-20. [PMID: 32420255 DOI: 10.21037/gs.2020.03.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
150 Wang KX, Du GH, Qin XM, Gao L. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling. Phytomedicine 2021;93:153781. [PMID: 34649212 DOI: 10.1016/j.phymed.2021.153781] [Reference Citation Analysis]
151 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Qian YY, Liu ZS, Yan HJ, Yuan YF, Levenson AS, Li K. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma. Biomed Pharmacother 2018;101:852-9. [PMID: 29635894 DOI: 10.1016/j.biopha.2018.03.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
153 Schöler D, Castoldi M, Jördens MS, Schulze-Hagen M, Kuhl C, Keitel V, Luedde T, Roderburg C, Loosen SH. Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series. PLoS One 2021;16:e0255983. [PMID: 34407090 DOI: 10.1371/journal.pone.0255983] [Reference Citation Analysis]
154 Shi Z, Yang W, Tang H, Li X. Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25851. [PMID: 34011050 DOI: 10.1097/MD.0000000000025851] [Reference Citation Analysis]